NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE. THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, The Netherlands, Oct. 28, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. ...

2025年10月24日，神经科技公司 ONWARD Medical 宣布完成超 5000万欧元（约4.1亿元人民币） 的增发融资。 这家公司以"让脊髓损伤患者重新获得运动能力"为使命，十年来默默深耕在一个极其艰难、但同样充满希望的医学领域。 这笔资金由一群"懂科技、看临床"的机构组成：全球假肢与外骨骼巨头 Ottobock 作为战略投资方再次加码，医疗科技投资机构 Invus 与 ASR Global Impact Equity Fund 共同参投。交易完成后，ONWARD 的现金储备将支持其运营至 2026 年底，也意味着公司在神经修复赛道的商业化征程，进入一个新的阶段。 这一体系包括三款彼此递进的核心产品： 这种体系化的布局，使 ONWARD 能够覆盖从 非侵入康复 到 闭环植入 的全路径，既能在短期内形成商业收入，也为长期的神经功能重建奠定技术基础。 "我们已经从研发公司转变为真正的商业化企业。" ONWARD CEO Dave Marver 在声明中写道，"这笔融资将帮助我们扩大 ARC-EX 系统的市场布局，同时推动下一代植入式系统 ARC-IM 的关键临床 研究。" 相关阅读： 五例成功植入！康复 ...

Core Insights - ONWARD Medical N.V. successfully raised EUR 50.85 million through an accelerated bookbuild offering, issuing 11.3 million new ordinary shares at an issue price of EUR 4.50 per share [1][2][5] Company Overview - ONWARD Medical is a leading neurotechnology company focused on therapies to restore movement and function in individuals with spinal cord injuries and other movement disabilities [10][11] - The company has developed the ARC Therapy and has received 10 Breakthrough Device designations from the FDA for its technologies [10] Investment Details - The private placement was supported by existing and new investors, including Ottobock SE & Co. KGaA as a cornerstone investor and healthcare specialist investor Invus [2][5] - The net proceeds from the private placement are expected to extend the company's cash runway through at least the end of 2026 [4][5] Use of Proceeds - The funds will be allocated as follows: - 40% for product development, clinical studies, and regulatory activities for the investigational ARC-IM System - 30% to expand sales and operations for the commercialization of the ARC-EX System - 20% to support quality and administrative activities - 5% for working capital and general corporate purposes - 5% to cover financing costs, including existing debt obligations [6] Market Activity - Trading of ONWARD Medical's shares was temporarily suspended during the bookbuilding period and is set to resume on October 24, 2025 [7] - The new shares are expected to be listed on Euronext Brussels, Euronext Amsterdam, and Euronext Paris on October 28, 2025 [8]

Core Insights - ONWARD Medical N.V. has appointed Lucas Buchanan as a non-executive member of its Board of Directors, enhancing its leadership team as it aims to grow its business and fulfill its mission to restore movement and function for individuals with spinal cord injuries and other movement disabilities [1][2] Company Overview - ONWARD Medical is a leading neurotechnology company focused on pioneering therapies to restore movement, function, and independence in individuals with spinal cord injuries (SCI) and other movement disabilities [4] - The company has developed ARC Therapy, which has received ten Breakthrough Device Designations from the US FDA, and its ARC-EX System is cleared for commercial sale in the US [4] - ONWARD is also working on an investigational implantable system called ARC-IM, which may include an implanted brain-computer interface (BCI) [4] Leadership and Expertise - Lucas Buchanan brings over 25 years of experience in commercialization, operations, business development, investing, and finance, having previously served as COO and CFO at Silk Road Medical, leading the company to its IPO in 2019 and subsequent acquisition by Boston Scientific in 2024 [2][6] - Buchanan is an active investor and currently serves on the boards of several medical technology companies, showcasing his extensive involvement in the healthcare sector [3][6] Strategic Vision - The appointment of Buchanan is seen as a strategic move to leverage his unique experiences as an operator and investor to help ONWARD Medical achieve its ambitions and deliver hope to millions affected by spinal cord injuries and movement disabilities [2][3]

Core Insights - ONWARD Medical N.V. announces changes to its Board of Directors, highlighting the appointment of Professor Tim Denison and the departure of Professor Gregoire Courtine [2][5][7] Company Overview - ONWARD Medical is a leading neurotechnology company focused on developing therapies to restore movement and function in individuals with spinal cord injuries (SCI) and other movement disabilities [10][11] - The company has developed ARC Therapy, which has received 10 Breakthrough Device Designations from the US FDA, and its ARC-EX System is cleared for commercial sale in the US [10] Board Changes - Professor Tim Denison has been appointed to the Board, taking over the seat previously held by Professor Gregoire Courtine, who will continue as Co-Founder and Science Advisor [3][5][8] - Denison brings extensive experience in neurotechnology, having previously served as Vice President of Research & Core Technology at Medtronic and is a co-founder of Amber Therapeutics [4][8] Research and Development Focus - The Neuro-X Institute, directed by Courtine, is a multidisciplinary research hub aimed at accelerating therapies for neurological disorders, while NeuroRestore focuses on recovery therapies for SCI, Parkinson's disease, and stroke [6][10] - ONWARD Medical's commitment to innovation is underscored by its ongoing development of investigational products, including the ARC-IM system [10][18]

Company Overview - ONWARD Medical N.V. is a leading neurotechnology company focused on developing therapies to restore movement, function, and independence for individuals with spinal cord injuries and other movement disabilities [3][4] - The company has developed ARC Therapy, which has received ten Breakthrough Device Designations from the US FDA [3] - The ARC-EX System is cleared for commercial sale in the US, while the investigational ARC-IM system is under development [3][9] Recent Developments - All proposed resolutions at the Annual General Meeting of Shareholders (AGM) held on June 11, 2025, in Amsterdam were approved [1][2] - The meeting took place at 4:00 PM CET, and details of the resolutions can be found on the company's Investor Relations website [2] Corporate Structure - ONWARD Medical is headquartered in the Netherlands, with a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts [4] - The company is listed on Euronext Paris, Brussels, and Amsterdam under the ticker ONWD, and its US ADRs are traded on OTCQX under the ticker ONWRY [4]

Core Points - ONWARD Medical N.V. is a medical technology company focused on developing spinal cord stimulation therapies to restore movement and independence for individuals with spinal cord injuries and other movement disabilities [1][3] - The company will hold its 2025 Annual General Meeting of Shareholders (AGM) on June 11, 2025, in Amsterdam, with a record date for participation set for May 14, 2025 [1][2] Company Overview - ONWARD Medical has developed ARC Therapy, which has received ten Breakthrough Device Designations from the US FDA, and its ARC-EX System is cleared for commercial sale in the US [3] - The company is also working on an investigational implantable system called ARC-IM, which may include a brain-computer interface [3] - The company is headquartered in the Netherlands, with additional facilities in Switzerland and a US office in Boston, Massachusetts [4] AGM Resolutions - Key resolutions proposed for the AGM include the adoption of annual accounts for the financial year 2024, implementation of the compensation policy for 2024, and the appointment of new non-executive directors [4] - The board seeks authorization to issue ordinary shares and acquire shares in the company's capital, with specific limits on the percentage of issued share capital [4]

Core Insights - ONWARD Medical N.V. has filed its Annual Report for the fiscal year ended December 31, 2024, with the Dutch Authority for the Financial Markets (AFM) [1] - The company has also released its 2024 Sustainability Report and received a silver medal from EcoVadis for business sustainability ratings [2] - CEO Dave Marver highlighted that 2024 was transformative for ONWARD, emphasizing the company's mission to restore movement and independence for individuals with spinal cord injuries [2] Company Overview - ONWARD Medical is focused on creating therapies aimed at restoring movement, function, and independence for people with spinal cord injuries and other movement disabilities [3] - The company has developed ARC Therapy, which has received ten Breakthrough Device Designations from the US FDA, and its ARC-EX System is cleared for commercial sale in the US [3] - ONWARD is also working on an investigational implantable system called ARC-IM, which may include a brain-computer interface [3] Locations and Listings - The company is headquartered in the Netherlands, with a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts [4] - ONWARD Medical is listed on Euronext Paris, Brussels, and Amsterdam under the ticker ONWD, and its US ADRs can be traded on OTCQX under the ticker ONWRY [4]